ID   EDi001-B-2
AC   CVCL_A1XQ
SY   AST18-7B
DR   BioSamples; SAMEA7111751
DR   EBiSC; EDi001-B-2
DR   ECACC; 66770009
DR   hPSCreg; EDi001-B-2
DR   Wikidata; Q105506812
RX   PubMed=30472757;
CC   From: University of Edinburgh; Edinburgh; United Kingdom.
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA.
CC   Discontinued: ECACC; 66770009; true.
CC   Derived from site: In situ; Skin, dermis; UBERON=UBERON_0002067.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
DI   NCIt; C198604; Parkinson disease 4, autosomal dominant
DI   ORDO; Orphanet_411602; Hereditary late-onset Parkinson disease
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_ZA47 ! EDi001-B
SX   Female
AG   55Y
CA   Induced pluripotent stem cell
DT   Created: 12-01-21; Last updated: 30-01-24; Version: 7
//
RX   PubMed=30472757; DOI=10.1111/ejn.14286;
RA   Chen Y.-X., Dolt K.S., Kriek M., Baker T., Downey P., Drummond N.J.,
RA   Canham M.A., Natalwala A., Rosser S., Kunath T.;
RT   "Engineering synucleinopathy-resistant human dopaminergic neurons by
RT   CRISPR-mediated deletion of the SNCA gene.";
RL   Eur. J. Neurosci. 49:510-524(2019).
//